[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596255":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":11,"responsibleParty":26,"collaborators":11,"id":28,"slug":11,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":11,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":11,"enrollmentInfo":36,"targetDuration":11,"studyType":39,"phases":40,"briefSummary":42,"conditions":43,"keywords":11,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":11},{"fullName":5,"class":6},"Caranx Medical","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TAVR procedure with TAVIPILOT (investigational medical device)","EXPERIMENTAL",null,[13],"Device: TAVR using a guidance software",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","TAVR using a guidance software","TAVR procedure with TAVIPILOT augmented reality guidance software operating in parallel on a separate screen in a blind setup, enabling clinicians to assess the analysis and recommendations provided by the software, either immediately after valve deployment or following the completion of the procedure.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Eric Sejor, MD","CONTACT","0033673335594","eric.sejor@caranx-medical.com",{"type":27,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100596255",false,"NCT07043075","First-in-Human (FIH) Study on the Feasibility and Safety of the TaviPilot Augmented Reality Guidance Software","First-in-Human (FIH) Study on the Feasibility and Safety of the TaviPilot Augmented Reality Guidance Software Operated in Parallel Setup During Transcatheter Aortic Valve Implantation (TAVI) Without Influencing Clinical Decision-Making","Inclusion Criteria:\n\n1. Patients aged ≥65\n2. Indicated for transfemoral TAVR for severe aortic stenosis","ALL","65 Years",{"count":37,"type":38},10,"ESTIMATED","INTERVENTIONAL",[41],"NA","The trial aims to evaluate the feasibility and safety of Caranx Medical TAVIPILOT augmented reality guidance software during Transcatheter Aortic Valve Replacement Procedures.",[44],"Aortic Valve Stenosis","NOT_YET_RECRUITING","2025-06-20",{"date":48,"type":49},"2025-06-29","ACTUAL",{"date":51,"type":38},"2025-08-01",{"date":53,"type":38},"2026-05-30",{"name":5,"class":6}]